SCD and MTHFD2 inhibitors for high-risk acute myeloid leukaemia patients, as suggested by ELN2017-pathway association.
Han Sun KimDoyeon KimJiwoo KimSunghyouk ParkArvie Camille V de GuzmanPublished in: Clinical and translational medicine (2023)
Keyphrases